Recognition of cisplatin adducts by cellular proteins

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 478, Issue 1-2, 2001, Pages 1-21

  Kartalou, Maria ^a   Essigmann, John M ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

3 Methyladenine DNA glycosylase; Cisplatin; DNA adducts; ERCCI; Histone H1; HMG box proteins; Mismatch reapir; Photolyase; RPA; T4 endonuclease VII and Ku autoantigen; TATA binding protein; trans DDP; XPA; XPE; Y box binding protein

Indexed keywords

ANTIINFECTIVE AGENT; CELL PROTEIN; CISPLATIN; DEOXYRIBODIPYRIMIDINE PHOTOLYASE; DNA; ENDONUCLEASE; HISTONE H1; HUMAN MENOPAUSAL GONADOTROPIN; KU ANTIGEN; OXALIPLATIN; PLATINUM; T4 ENDONUCLEASE VII; TATA BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL DEATH; CELL SURVIVAL; CROSS LINKING; DNA ADDUCT; DNA REPAIR; DRUG EFFICACY; DRUG STRUCTURE; EXCISION REPAIR; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; XERODERMA PIGMENTOSUM;

ANIMALS; ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS; CISPLATIN; DEOXYRIBODIPYRIMIDINE PHOTO-LYASE; DNA ADDUCTS; DNA HELICASES; DNA REPAIR; DNA-BINDING PROTEINS; HIGH MOBILITY GROUP PROTEINS; HUMANS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEINS;

EID: 0035400494     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(01)00142-7     Document Type: Article

References (161)

1. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode
2. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes
3. Cis-dichlorodiammineplatinum(II): Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo
4. Platinum compounds: A new class of potent antitumour agents
5. Inhibition of Dunning ascitic leukemia and Walker 256 carcinosarcoma with cis-diamminedichloroplatinum (NSC-119875)
6. Growth inhibition of rat mammary carcinoma induced by cis-platinumdiamminodichloride(II)
7. Effect of cis-platinum(II)diamminodichloride on wild type and deoxyribonucleic acid repair-deficient mutants of Escherichia coli
8. Effects of anticancer platinum compounds on Escherichia coli strains with normal and defective DNA repair capacity
9. Mechanism of toxicity of platinum(II) compounds in repair-deficient strains of Escherichia coli
10. Reactions of the Uvr(A)BC excision nuclease with DNA damaged by diamminedichloroplatinum(II)
11. Studies on mutagenesis and repair induced by platinum analogs
12. Repair of plasmid DNA damaged in vitro with cis- or trans-diamminedichloroplatinum(II) in Escherichia coli
13. Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus
14. Host-cell reactivation of cis-diamminedichloroplatinum(II)-treated SV40 DNA in normal human, Fanconi anaemia and xeroderma pigmentosum fibroblasts
15. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts
16. Quantitation of cis-diamminedichloroplatinum(II) (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy
17. The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration
18. Interactions between mammalian cell DNA and inorganic platinum compounds(I)
19. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA
20. Biological processing of DNA modified by platinum compounds
21. 195Pt NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA
22. Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA
23. Characterization of the adducts produced in DNA be cis-diamminedichloroplatinum(II) and cis-dichloro(ethy-lenediamine)platinum(II)
24. Interstrand cross-links and sequence specificity in the reaction of cis-dichloro(ethylenediamine)platinum(II) with DNA
25. Cis-diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: Quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II)
26. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: Formation, identification, and quantitation
27. The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: Application of immunochemical techniques
28. Interaction of trans-diamminedichloroplatinum(II) with DNA: Formation of monofunctional adducts and their reaction with glutathione
29. Characterization of bifunctional adducts produced in DNA by trans-diamminedichloroplatinum(II)
30. DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues
31. The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by ≫40° toward the major groove
32. Distortions induced in double-stranded oligonucleotides by the binding of cis- or trans-diamminedichloroplatinum(II) to the d(GTG) sequence
33. +
34. Conformation of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diamminedichloroplatinum(II)
35. Base sequence-independent distortions induced by interstrand cross-links in cis-diamminedichloroplatinum(II)-modified DNA
36. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II)
37. Crystal structure of the anticancer drug cisplatin bound to duplex DNA
38. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin
39. NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin
40. Structure and isomerization of an intrastrand cisplatin-cross-linked octamer DNA duplex by NMR analysis
41. Structure of a nonanucleotide duplex cross-linked by cisplatin at an ApG sequence
42. RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum(II)
43. Replication inhibition and translation synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts
44. Solution structure of a DNA duplex containing a cis-diammineplatinum(II) 1,3-d(GTG) intrastrand cross-link, a major adduct in cells treated with the anticancer drug carboplatin
45. 2[d(-GTG-)-N7(G),N7(G)] adduct, as determined with high-field NMR and molecular mechanics/dynamics
46. Solution structure of a cisplatin-induced DNA interstrand cross-link
47. NMR solution structure of a DNA docamer containing an interstrand cross-link of the antitumor drug cis-diamminedichloroplatinum(II)
48. Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: Hydration at the platinated site
49. NMR solution structure of a DNA dodecamer containing a transplatin interstrand GN7-CN3 cross-link
50. HMG domain proteins: Architectural elements in the assembly of nucleoprotein structures
51. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin
52. Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II)
53. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin
54. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin
55. Isolation and characterization of cDNA clones encoding the Drosophila homolog of the HMG-box SSRP family that recognizes specific DNA structures
56. Purification of nuclear proteins that bind to cisplatin-damaged DNA
57. Characterization of high mobility group protein binding to cisplatin-damaged DNA
58. Cisplatin-DNA binding specificity of calf high-mobility group 1 protein
59. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin
60. HMG-D is an architecture-specific protein that preferentially binds to DNA containing the dinucleotide TG
61. The high mobility group domain protein Cmb1 of Schizosaccharomyces pombe binds to cytosines in base mismatches and opposite chemically altered guanines
62. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor)
63. HMG domain proteins induce sharp bends in cisplatin-modified DNA
64. I × r1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin
65. Binding of I × r1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo
66. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts
67. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities
68. DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA
69. Stopped-flow fluorescence studies of HMG-domain protein binding to cisplatin-modified DNA
70. Structural basis for DNA bending by the architectural transcription factor LEF-1
71. NMR spectroscopic analysis of the DNA conformation induced by the human testis determining factor SRY
72. Molecular basis of human 46X, Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex
73. Solution structure of the HMG protein NHP6A and its interaction with DNA reveals the structural determinants for non-sequence-specific binding
74. An SRY mutation causing human sex reversal resolves a general mechanism of structure-specific DNA recognition: Application to the four-way DNA junction
75. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins
76. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans-isomer by DNA-binding proteins
77. Crystal structure of a G: T/U mismatch-specific DNA glycosylase: Mismatch recognition by complementary-strand interactions
78. Crystal structure of a human alkylbase-DNA repair enzyme complexed to DNA: Mechanisms for nucleotide flipping and base excision
79. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor
80. Cisplatin inhibits synthesis of ribosomal RNA in vivo
81. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease
82. Repair of cisplatin-DNA adducts by the mammalian excision nuclease
83. Human replication protein A preferentially binds cisplatin-damaged duplex DNA in vitro
84. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro
85. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin
86. The HMG-domain protein I × r1 blocks excision repair of cisplatin-DNA adducts in yeast
87. DNA lesion-recognizing proteins and the p53 connection
88. The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA
89. Co-crystal structure of TBP recognizing the minor groove of a TATA element
90. Crystal structure of a yeast TBP/TATA-box complex
91. Crystal structure of a human TATA box-binding protein/TATA element complex
92. Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP
93. TATA binding protein discriminates between different lesions on DNA, resulting in a transcription decrease
94. Enhanced binding of the TATA-binding protein to TATA boxes containing flanking cisplatin 1,2-cross-links
95. A single d(GpG) cisplatin adduct on the estrogen response element decreases the binding of the estrogen receptor
96. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene
97. Role of the human Y-box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light
98. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen
99. Evidence for dinucleotide flipping by DNA photolyase
100. Escherichia coli DNA photolyase stimulates Uvr(A)BC excision nuclease in vitro
101. The other function of DNA photolyase: Stimulation of excision repair of chemical damage to DNA
102. DNA bending by photolyase in specific and non-specific complexes studied by atomic force microscopy
103. A novel role for DNA photolyase: Binding to DNA damaged by drugs is associated with enhanced cytotoxicity in Saccharomyces cerevisiae
104. Evidence that xeroderma pigmentosum cells from complementation group E are deficient in a homolog of yeast photolyase
105. Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA
106. Xeroderma pigmentosum group E binding factor recognizes a broad spectrum of DNA damage
107. Induction of UV-damage recognition protein by cisplatin treatment
108. Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA
109. Correction of the DNA repair defect in xeroderma pigmentosum group E by injection of a DNA damage-binding protein
110. Relationship of the xeroderma pigmentosum group E DNA repair defect to the chromatin and DNA binding proteins UV-DDB and replication protein A
111. Preferential binding of the xeroderma pigmentosum group A complementing protein to damaged DNA
112. The XPA protein is a zinc metalloprotein with an ability to recognize various kinds of DNA damage
113. Identification of a damaged-DNA binding domain of the XPA protein
114. Photocrosslinking locates a binding site for the large subunit of human replication protein A to the damaged strand of cisplatin-modified DNA
115. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy
116. Expression of nucleotide excision repair genes in CDDP-sensitive and resistant human ovarian cancer cell lines
117. Enhancement of damage-specific DNA binding of XPA by interaction with the ERCC1 DNA repair protein
118. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer
119. ERCC1 expression correlates with response of primary gastric cancer to cisplatin-based chemotherapy
120. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients
121. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours
122. Binding of human single stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum(II)
123. Replication protein A (RPA) binding to duplex cisplatin-damaged DNA is mediated through the generation of single-stranded DNA
124. Replication protein A confers structure-specific endonuclease activities to the XPF-ERCC1 and XPG subunits of human DNA repair excision nuclease
125. Open complex formation around a lesion during nucleotide excision repair provides a structure for cleavage by human XPG protein
126. DNA-binding polarity of human replication protein A positions nucleases in nucleotide excision repair
127. Mutator phenotypes in human colorectal carcinoma cell lines
128. Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells
129. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6
130. Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair
131. hMutSβ, a heterodimer of hMSH2 and hMSH3, binds to insertion/deletion loops in DNA
132. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin
133. 4-methylthymine
134. Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems
135. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins
136. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells
137. Loss of DNA mismatch repair in acquired resistance to cisplatin
138. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line
139. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents
140. The role of DNA mismatch repair in platinum drug resistance
141. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts
142. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
143. Mutator phenotype in Msh2-deficient murine embryonic fibroblasts
144. Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and N-methyl-N′-nitro-N-nitrosoguanidine
145. 2 cell cycle checkpoint
146. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents
147. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin
148. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells
149. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
150. Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts
151. 3-Methyladenine DNA glycosylases: Structure, function, and biological importance
152. 6-ethenoadenine repair by interacting with the human 3-methyladenine DNA glycosylase
153. 3-Methyladenine-DNA glycosylase (MPG protein) interacts with human RAD23 proteins
154. T4 endonuclease VII cleaves DNA containing a cisplatin adduct
155. UV sensitivity and impaired nucleotide excision repair in DNA-dependent protein kinase mutant cells
156. Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II): Role of Ku autoantigen
157. Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase
158. Mechanism of DNA-dependent protein kinase inhibition by cis-diamminedichloroplatinum(II)-damaged DNA
159. Interactions of mammalian proteins with cisplatin-damaged DNA
160. Modulation of radiation-induced strand break repair by cisplatin in mammalian cells